NCT04198766 2025-12-18Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)Inhibrx Biosciences, IncPhase 1/2 Active not recruiting296 enrolled
NCT07162883 2025-09-09Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)Qilu Pharmaceutical Co., Ltd.Phase 3 Not yet recruiting122 enrolled
NCT03769467 2024-11-14Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)Atara BiotherapeuticsPhase 1/2 Terminated12 enrolled 8 charts
NCT02981524 2021-02-10Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal CancerSidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 2 Completed17 enrolled 12 charts